middle.news
Neurizon advances NUZ-001 as first ALS participant enters active extension
9:39am on Friday 13th of November, 2026 AEDT
•
Biotechnology
Read Story
Neurizon advances NUZ-001 as first ALS participant enters active extension
9:39am on Friday 13th of November, 2026 AEDT
Key Points
First participant completes 36-week placebo-controlled phase
Optional 36-week extension provides longer-term safety and biomarker data
Regimen I fully enrolled with 250 participants across 78 US sites
Topline randomised trial results expected in late Q2 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE